BCM
SAGE

BCK Capital Management’s Sage Therapeutics SAGE Stock Holding History

BCK Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-297,040
Closed -$2.71M – 108
2025
Q2 		$2.71M Buy
+297,040
New +$2.18M 2.34% 9

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

BCK Capital Management's SAGE Position: Q3 2025 in Review

BCK Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 297,040 shares — an estimated $2.71M sold.

BCK Capital Management first reported a position in SAGE in Q2 2025 and held it in 1 quarter. The position peaked at $2.71M in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • BCK Capital Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • BCK Capital Management sold 297,040 Sage Therapeutics shares in Q3 2025, an estimated $2.71M.
  • BCK Capital Management first reported a position in Sage Therapeutics in Q2 2025 and held it in 1 quarter.
  • BCK Capital Management's Sage Therapeutics position peaked at $2.71M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on BCK Capital Management's 13F filing for Q3 2025, filed 10 Nov 2025.